3 Ongoing studies
Table 1 summarises the available information on evidence gaps and ongoing studies that might address them. More information on the studies in the table can be found in the supporting documents.
|
Evidence gap |
AI-Rad (Siemens Healthineers) |
Red Dot (Behold.ai) |
qXR (Qure.ai) |
|
|---|---|---|---|---|
|
Impact of software on clinical decision making and number of people referred to have a CT scan |
No relevant evidence identified |
No relevant evidence identified |
No relevant evidence identified |
No relevant evidence identified Ongoing study |
|
Time from chest X-ray review and report |
No relevant evidence identified |
Limited current evidence |
No relevant evidence identified Ongoing study |
No relevant evidence identified Ongoing study |
|
Time to CT referral |
No relevant evidence identified |
No relevant evidence identified |
No relevant evidence identified Ongoing study |
No relevant evidence identified Ongoing study |
|
Time to diagnosis |
No relevant evidence identified |
No relevant evidence identified |
No relevant evidence identified |
No relevant evidence identified Ongoing study |
|
Diagnostic accuracy, agreement, and technical failure rates |
Limited current evidence |
Limited current evidence |
Limited current evidence Ongoing study |
No relevant evidence identified Ongoing studies |
|
Software impact on healthcare costs and resource use |
No relevant evidence identified |
No relevant evidence identified |
No relevant evidence identified |
No relevant evidence identified Ongoing study |
|
Software performance for people with underlying conditions and high-risk groups |
No relevant evidence identified |
No relevant evidence identified |
No relevant evidence identified |
No relevant evidence identified |
|
Clinician and patient perceptions on the use of artificial intelligence (AI)-derived software |
No relevant evidence identified |
No relevant evidence identified |
No relevant evidence identified |
No relevant evidence identified |
Information about current evidence status is from the external assessment group (EAG) report. Evidence not meeting the scope and inclusion criteria is not included.
The following technologies did not have evidence that met the scope and inclusion criteria for these evidence gaps: Annalise CXR (annalise.ai), Auto Lung Nodule Detection (Samsung), Chestlink Radiology Automation (Oxipit), Chestview (GLEAMER), Chest X-ray (Rayscape), InferRead DR Chest (Infervision), Milvue Suite (Milvue), SenseCare-Chest DR Pro (Sensetime), and VUNO Med-Chest X-ray (VUNO).